Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234950 | 0.87 | ALDH1A1 (0.58) | NPSR1KDM4EMAPTHPGDPOLB | |
| SCHEMBL5681855 | 0.76 | NPSR1 (0.59) | NPSR1KDM4EMAPTHPGDPOLB | |
| SCHEMBL4739312 | 0.75 | CYP2A6 (0.34) | SMN1; SMN2ALDH1A1L3MBTL1CYP2A6KIF11 | |
| SCHEMBL889055 | 0.75 | CYP2A6 (0.44) | KDM4EMAPTHPGDPOLBSMN1; SMN2 | |
| SCHEMBL29957251 | 0.75 | CYP2A6 (0.44) | KDM4EMAPTHPGDPOLBSMN1; SMN2 | |
| SCHEMBL2361718 | 0.75 | CYP2A6 (0.44) | KDM4EALDH1A1HSD17B10CYP2A6KIF11 | |
| SCHEMBL4742869 | 0.75 | ALDH1A1 (0.48) | ALDH1A1CYP2A6KIF11MEN1KMT2A | |
| SCHEMBL7245705 | 0.75 | CYP2A6 (0.44) | KDM4EMAPTHPGDALDH1A1CYP2A6 | |
| SCHEMBL19364798 | 0.75 | CYP2A6 (0.44) | KDM4EMAPTHPGDPOLBSMN1; SMN2 | |
| SCHEMBL1284461 | 0.75 | NPSR1 (0.58) | NPSR1KDM4EMAPTHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233797-B1 | MAP4K4 (HGK) INHIBITORS | Sri int inc (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | SRI INTERNATIONAL (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3233797-A1 | MAP4K4 (HGK) Inhibitors | SRI International Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016114816-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2016-07-21 | — | — | WO | disclosed |
| US-6399642-B2 | TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-06-04 | — | — | US | disclosed |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-07-26 | — | — | US | disclosed |
| US-6221892-B1 | Heterocyclic topoisomerase poisons | THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS | 2001-04-24 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-RE33948-E | Bactericides, animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| US-4748163-A | Novel β-lactam antibiotics | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-31 | — | — | US | disclosed |
| EP-0195947-A2 | Beta-lactam antibiotics, process for their preparation and their use as and in medicaments | BAYER AG (DE) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | MAP4K4, MAP4K2, MAP4K3 | NPSR1 4052/4885KDM4E 971/4885MAPT 308/4885 |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | TOP1, TOP2A, TOP2B | NPSR1 4090/4885KDM4E 2275/4885MAPT 3332/4885 |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | MAP4K4, MAP4K2, MAP4K3 | NPSR1 4052/4885KDM4E 971/4885MAPT 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.